脑电图微状态不稳定性与精神病临床高风险个体的临床结局
本研究基于北美前驱期纵向研究-2(NAPLS-2)8个中心的数据,分析精神病临床高风险(CHR)个体静息态脑电图微状态特征与24个月内转化为精神病及其他临床结局的关联。结果发现CHR个体较健康对照微状态时间稳定性降低,且未来转化者不稳定程度更高;较低稳定性与更早转化及阳性症状增加相关,并与更好的注意力得分相关。
要点
- CHR个体较健康对照显示微状态持续时间缩短、出现频率增加,反映时间稳定性降低。
- 未来转化为精神病者微状态不稳定程度高于缓解者和健康对照,但与症状持续者无差异。
- 较低微状态稳定性与更早转化和阳性症状增加相关,提示其作为预后生物标志物的潜力。
核心结论
- CHR个体静息态EEG微状态稳定性较健康对照降低,未来转化者尤为明显。
- 较低微状态稳定性与更早转化为精神病及阳性症状增加相关。
- 微状态不稳定性有望作为CHR临床结局的预后生物标志物。
研究设计与样本
- 研究为8中心病例对照的北美前驱期纵向研究-2(NAPLS-2),基线EEG数据收集于2009年10月至2014年8月。
- 纳入健康对照183例、CHR个体460例,其中CHR转化者56例、非转化者中缓解70例、症状持续115例。
- CHR个体中241例(52.4%)完成24个月完整随访,数据分析于2025年1月至11月进行。
主要发现
- CHR个体较健康对照微状态持续时间缩短(Cohen d=0.28,95%CI 0.07-0.49),出现频率增加(Cohen d=0.12,95%CI 0.03-0.21)。
- CHR转化者微状态不稳定程度高于缓解者和健康对照,但与症状持续者无显著差异。
- 在CHR组内,较低稳定性与更早转化和阳性症状增加相关。
- CHR个体较健康对照存在认知缺陷包括注意力得分,但较低微状态稳定性与两组中更好的注意力得分相关。
临床怎么用
- 静息态EEG微状态稳定性可作为CHR个体预后评估的潜在生物标志物,辅助识别转化风险较高者。
- 微状态不稳定与更好注意力相关,解读时需考虑其可能反映代偿机制而非单纯缺陷。
局限性
- CHR个体中仅52.4%完成24个月完整随访,可能存在失访偏倚。
- 微状态不稳定与症状持续者无差异,其区分转化与持续症状的能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical criteria for identifying individuals at clinical high risk of psychosis (CHR) have been established, but their predictive accuracy remains insufficient for guiding treatment decisions. Identifying reliable biomarkers associated with mechanisms of illness and treatment in individuals at CHR is therefore a central research goal. Here, we consider resting-state electroencephalography (EEG) microstates as such a potential biomarker. OBJECTIVE: To determine whether EEG microstate features are associated with future conversion to psychosis and other future clinical outcomes in individuals at CHR. DESIGN, SETTING, AND PARTICIPANTS: Baseline EEG microstate data were collected from October 2009 through August 2014 as part of the 8-site case-control North American Prodrome Longitudinal Study-2 (NAPLS-2) during eyes-open resting-state conditions with continuous auditory white noise. Data were recorded from healthy control (HC) individuals and participants at CHR, including those at CHR with conversion to psychosis (CHR-C) and those with nonconversion (CHR-NC), followed up for 24 months. Individuals with CHR-NC were further divided into those with remission (CHR-R) or those with ongoing symptomatology (CHR-S) subgroups. A total of 241 individuals at CHR (52.4%) completed the full 24-month follow-up. Data were analyzed between January and November 2025. MAIN OUTCOMES AND MEASURES: Resting-state EEG microstate features (coverage, duration, and occurrence) across 7 distinct microstate classes, along with cognitive test battery scores. RESULTS: Compared with HC participants (n = 183; 103 [56.3%] male; mean [SD] age, 20.2 [5.0] years), individuals at CHR (n = 460; 265 [57.6%] male; mean [SD] age, 19.2 [4.4] years) showed reduced microstate duration (Cohen d, 0.28; 95% CI, 0.07 to 0.49) and increased occurrence (Cohen d, 0.12; 95% CI, 0.03 to 0.21) across classes, reflecting reduced microstate temporal stability. Moreover, individuals with CHR-C (n = 56) exhibited greater instability than those with CHR-R (n = 70) and HC participants but not compared to those with CHR-S (n = 115). Within the CHR group, lower stability was associated with earlier conversion to psychosis and with increased positive symptoms. While individuals at CHR demonstrated cognitive deficits relative to HC participants, including attention scores, lower microstate stability was associated with better attention scores in both groups. CONCLUSIONS AND RELEVANCE: In this study, EEG microstate stability, irrespective of class, was reduced in individuals at CHR compared to HC participants and was especially diminished in future CHR converters. The association between lower stability and better attention suggests that instability may at least partly reflect a compensatory mechanism for attention deficits. EEG microstate instability shows promise as a prognostic biomarker of clinical outcome in CHR.
引用
- Liebrand M, Hamilton HK, Roach BJ, et al. Electroencephalography Microstate Instability and Clinical Outcomes in Individuals at Clinical High Risk of Psychosis. JAMA Psychiatry. 2026. PMID: 42234419. doi:10.1001/jamapsychiatry.2026.1084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。